Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
about
Biologics registers in RA: methodological aspects, current role and future applications.High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation.Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Improving Donor Livers by Inhibiting TNF-α Production.Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialRheumatoid hand surgery: is there a decline? A 22-year population-based study.Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment.The BSRBR-RA at 15 years.The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.Tocilizumab: is there life beyond anti-TNF blockade?Genetics and the impact on treatment protocols in patients with rheumatoid arthritis.Leukocyte production of inflammatory mediators is inhibited by the antioxidants phloretin, silymarin, hesperetin, and resveratrol.Does disease activity at start of biologic therapy influence work-loss in RA patients?Does disease activity at the start of biologic therapy influence health care costs in patients with RA?Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s.Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database.Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy
P2860
Q30234303-74438ED6-0DC6-421F-97CF-C9BD23707F71Q30662067-5735E069-EB42-4A27-83BF-4F47DEA56E00Q33932158-176FCD93-C1A1-42F4-9E0A-D8D318B0E815Q33962865-CDA042C9-A7A0-4536-AB4E-CE351196724FQ34208252-328EAA4A-232F-4ACE-80F8-C5181E0B6115Q34986286-31DA7B01-BF0E-44A7-AA5C-1096DCEAFB14Q35351313-DF91BD46-8754-4EFE-98CC-1C64EF5BD1B1Q35661467-023B87F6-BD06-4703-8487-4A37C94149E9Q36183760-B7BFD96A-5086-4ADA-A031-FFAE9303B1A7Q37333943-F3AD4687-4FB8-42E5-86BD-5B0831DA5C0DQ37383424-3A738DB2-01C6-452D-91EC-1F568791F596Q37471597-41FBBB4C-482C-42F6-AE43-1B61D641B539Q37832771-33D0775F-8CDB-468C-AC5A-DDA4FFA5CBD6Q38044756-5C61E14B-4EA0-41FD-A0AE-A31949C291A0Q38269769-7A28682F-1F99-490F-88BD-98747A467BD4Q38410704-44D7E743-B74B-46DE-BE41-A2FFFD40141FQ41183360-0F00C1CA-F285-4B7B-80F7-3622CC8E6295Q45369749-BB1070D0-C972-4C6B-8B02-1DB971B62356Q51458036-75709766-E4B8-489E-8EF2-D7C28FCD3F20Q51650310-C955A481-2324-4502-A8A2-B5A4A8F3A9D3Q53441582-432A585E-B203-4678-8189-CD9DAC2BAF1CQ58327971-7ABC7DA7-9005-479F-B468-51681EA6AC40
P2860
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefit of anti-TNF therapy in ...... with moderate disease activity
@en
Benefit of anti-TNF therapy in ...... ith moderate disease activity.
@nl
type
label
Benefit of anti-TNF therapy in ...... with moderate disease activity
@en
Benefit of anti-TNF therapy in ...... ith moderate disease activity.
@nl
prefLabel
Benefit of anti-TNF therapy in ...... with moderate disease activity
@en
Benefit of anti-TNF therapy in ...... ith moderate disease activity.
@nl
P2093
P2860
P356
P1433
P1476
Benefit of anti-TNF therapy in ...... with moderate disease activity
@en
P2093
BSRBR Control Centre Consortium
British Society for Rheumatology Biologics Register
Chris Deighton
Kath D Watson
Kimme L Hyrich
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEP242
P577
2009-08-25T00:00:00Z